Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

731 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrating a multimodal lifestyle intervention with medical food in prodromal Alzheimer's disease: the MIND-ADmini randomized controlled trial.
Thunborg C, Wang R, Rosenberg A, Sindi S, Andersen P, Andrieu S, Broersen LM, Coley N, Couderc C, Duval CZ, Faxen-Irving G, Hagman G, Hallikainen M, Håkansson K, Kekkonen E, Lehtisalo J, Levak N, Mangialasche F, Pantel J, Rydström A, Stigsdotter-Neely A, Wimo A, Ngandu T, Soininen H, Hartmann T, Solomon A, Kivipelto M. Thunborg C, et al. Among authors: hartmann t. Alzheimers Res Ther. 2024 May 30;16(1):118. doi: 10.1186/s13195-024-01468-x. Alzheimers Res Ther. 2024. PMID: 38812047 Free PMC article. Clinical Trial.
Communication about diagnosis, prognosis, and prevention in the memory clinic: perspectives of European memory clinic professionals.
Hendriksen HMA, van Gils AM, van Harten AC, Hartmann T, Mangialasche F, Kamondi A, Kivipelto M, Rhodius-Meester HFM, Smets EMA, van der Flier WM, Visser LNC. Hendriksen HMA, et al. Among authors: hartmann t. Alzheimers Res Ther. 2023 Aug 5;15(1):131. doi: 10.1186/s13195-023-01276-9. Alzheimers Res Ther. 2023. PMID: 37543608 Free PMC article.
Correction: A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer's disease.
van Oudenhoven FM, Swinkels SHN, Soininen H, Kivipelto M, Hartmann T, Rizopoulos D; LipiDiDiet clinical study group. van Oudenhoven FM, et al. Among authors: hartmann t. Alzheimers Res Ther. 2023 Oct 30;15(1):188. doi: 10.1186/s13195-023-01290-x. Alzheimers Res Ther. 2023. PMID: 37904252 Free PMC article. No abstract available.
Programme Dementia Prevention (pdp): A Nationwide Program for Personalized Prevention in Luxembourg.
Schröder VE, Skrozic A, Erz D, Kaysen A, Fritz JV, Loureiro JM, McIntyre D, Pauly L, Kemp J, Schmitz SK, Wagner S, Reyes M, Soare R, Satagopam V, Vega C, Gawron P, Roomp K, Conde PM, Klucken J, Köhler S, Hartmann T, Dodel R, Leist AK, Kalbe E, Krüger R. Schröder VE, et al. Among authors: hartmann t. J Alzheimers Dis. 2024;97(2):791-804. doi: 10.3233/JAD-230794. J Alzheimers Dis. 2024. PMID: 38189752 Free PMC article.
Nutrition guidance within a multimodal intervention improves diet quality in prodromal Alzheimer's disease: Multimodal Preventive Trial for Alzheimer's Disease (MIND-ADmini).
Levak N, Lehtisalo J, Thunborg C, Westman E, Andersen P, Andrieu S, Broersen LM, Coley N, Hartmann T, Irving GF, Mangialasche F, Ngandu T, Pantel J, Rosenberg A, Sindi S, Soininen H, Solomon A, Wang R, Kivipelto M. Levak N, et al. Among authors: hartmann t. Alzheimers Res Ther. 2024 Jul 3;16(1):147. doi: 10.1186/s13195-024-01522-8. Alzheimers Res Ther. 2024. PMID: 38961421 Free PMC article. Clinical Trial.
Author Correction: A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma.
Ryl T, Afanasyeva E, Hartmann T, Schwermer M, Schneider M, Schröder C, Wagemanns M, Bister A, Kanber D, Steenpass L, Schramm K, Jones B, Jones DTW, Biewald E, Astrahantseff K, Hanenberg H, Rahmann S, Lohmann DR, Schramm A, Ketteler P. Ryl T, et al. Among authors: hartmann t. Commun Biol. 2024 Sep 11;7(1):1119. doi: 10.1038/s42003-024-06830-1. Commun Biol. 2024. PMID: 39261566 Free PMC article. No abstract available.
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis.
Luciano M, Sieberer H, Krenn PW, Dang HH, Vetter J, Neuper T, Amend D, Blöchl C, Weichenberger CX, Eglseer A, Unger MS, Andosch A, Steiner P, Neureiter D, Bauer R, Hummer L, Tesanovic S, Binder S, Elmer DP, Strandt H, Schaller S, Strunk D, Pleyer L, Greil R, Winkler S, Hartmann TN, Schmidt-Arras D, Huber CG, Aberger F, Horejs-Hoeck J. Luciano M, et al. Among authors: hartmann tn. Cell Commun Signal. 2024 Sep 2;22(1):424. doi: 10.1186/s12964-024-01777-6. Cell Commun Signal. 2024. PMID: 39223663 Free PMC article.
731 results